Sargramostim: all 158 studies that test it

Page 1 of 2. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.

• N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With NeuroblastomaRecruitingNCT06528496Phase 2
• Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's DiseaseRecruitingNCT04902703Phase 2
• GM-CSF With Post-Transplant CyclophosphamideRecruitingNCT04237623Phase 2
• Sargramostim Use in COVID-19 to Recover Patient HealthCompletedNCT04707664Phase 2Results posted
• A Phase II/III Study of SargramostimCompletedNCT04642950Phase 2/3Results posted
• Study of Sargramostim in Patients With COVID-19CompletedNCT04411680Phase 2Results posted
• Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)Active, not recruitingNCT04385277Phase 2Results posted
• Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk NeuroblastomaCompletedNCT03786783Phase 2Results posted
• High-Risk Neuroblastoma Chemotherapy Without G-CSFCompletedNCT02786719Not applicableResults posted
• Pembrolizumab and GM-CSF in Biliary CancerCompletedNCT02703714Phase 2Results posted
• Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD ProphylaxisCompletedNCT02593123Phase 2Results posted
• Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent OsteosarcomaCompletedNCT02484443Phase 2Results posted
• Safety and Efficacy of Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV-1 ReservoirCompletedNCT02092116Phase 1/2Results posted
• Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By SurgeryCompletedNCT01989572Phase 3Results posted
• Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDSCompletedNCT01700673Phase 2Results posted
• Inhaled Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Hereditary Pulmonary Alveolar Proteinosis (PAP)CompletedNCT01511068Phase 2Results posted
• Study of the Safety & Efficacy of Leukine® in the Treatment of Alzheimer's DiseaseCompletedNCT01409915Phase 2Results posted
• Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory NeuroblastomaCompletedNCT01334515Phase 2Results posted
• Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling DonorsCompletedNCT01158118Phase 2Results posted
• Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryActive, not recruitingNCT01134614Phase 2Results posted
• Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With NeuroblastomaCompletedNCT01041638Phase 3Results posted
• Lenalidomide and GM-CSF in Treating Patients With Prostate CancerCompletedNCT00939510Phase 1/2Results posted
• GM-CSF in Treating Patients With Relapsed Prostate CancerCompletedNCT00908141Phase 2Results posted
• Inhaled GM-CSF Therapy of Autoimmune PAPCompletedNCT00901511Phase 2Results posted
• Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00643097Phase 2Results posted
• Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic LeukemiaCompletedNCT00562328Phase 2Results posted
• GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin LymphomaCompletedNCT00521014Phase 2Results posted
• Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung CancerCompletedNCT00514215Phase 2Results posted
• Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous ChemotherapyCompletedNCT00466960Phase 2Results posted
• MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic LeukemiaCompletedNCT00462605Phase 2Results posted
• 153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate CancerCompletedNCT00450619Phase 2Results posted
• Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell LymphomaCompletedNCT00411086Phase 2Results posted
• GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk Prostate CancerCompletedNCT00400517Phase 2Results posted
• FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic LeukemiaCompletedNCT00381004Phase 2Results posted
• Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKICompletedNCT00363649Phase 2Results posted
• Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia PatientsCompletedNCT00323557Phase 2Results posted
• Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's LymphomaTerminatedNCT00308087Phase 2Results posted
• GM-CSF Mouthwash for Preventing and Treating Mucositis in Patients Undergoing Radiation Therapy for Head and Neck CancerCompletedNCT00293462Phase 3Results posted
• Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant MelanomaCompletedNCT00256282Phase 2Results posted
• GM-CSF, Sargramostim in Women With Recurrent Ovarian CancerCompletedNCT00157573Phase 2Results posted
• Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal CancerCompletedNCT00103142Phase 2Results posted
• PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced CancerCompletedNCT00088413Phase 1/2Results posted
• Inhaled Sargramostim in Treating Patients With First Pulmonary (Lung) Recurrence of OsteosarcomaCompletedNCT00066365Phase 2Results posted
• NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/DisordersCompletedNCT00053989Phase 2Results posted
• Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With NeuroblastomaCompletedNCT00026312Phase 3Results posted
• Vaccine Therapy Following Chemotherapy & Peripheral Stem Cell Transplantation in Treating Non-Hodgkin's LymphomaTerminatedNCT00006478Phase 2Results posted
• Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast CancerCompletedNCT00003199Phase 2Results posted
• Biomarker Validation Following Sargramostim Treatment in Parkinson's DiseaseCompletedNCT05677633Phase 1
• Trial to Evaluate Safety and Efficacy of GM-CSF /Sargramostim in Down SyndromeWithdrawnNCT05482334Phase 2
• Study to Evaluate Pharmacokinetics, Pharmacodynamics, and Safety of Sargramostim Administered Subcutaneously, Intravenously, or by InhalationCompletedNCT05366283Phase 1
• Sargramostim With Ipilimumab Containing Therapy in Patients With Solid TumorsWithdrawnNCT05284214Phase 2
• Sargramostim (GM-CSF) + PD-1WithdrawnNCT04703426Phase 2
• Using GM-CSF as a Host Directed Therapeutic Against COVID-19CompletedNCT04400929Phase 2
• TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and SurgeryStatus unknownNCT04197687Phase 2
• Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine TumorsCompletedNCT03879694Phase 1
• Biomarker Assessments of Leukine During Treatment of Parkinson's DiseaseCompletedNCT03790670Phase 1
• Sargramostim for Myeloid Dendritic Cell DeficiencyTerminatedNCT03063242Phase 2
• Evaluation of a Single Dose of Inhaled Sargramostim in Patients With Autoimmune Pulmonary Alveolar ProteinosisCompletedNCT03006146Phase 1
• SK-1401 (rhGM-CSF Agent for Inhalation) GM-CSF Inhalation Pharmacokinetic StudyCompletedNCT02840708Phase 1
• Pulmonary Alveolar Proteinosis GM-CSF Inhalation Efficacy Trial in JapanCompletedNCT02835742Phase 2
• Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's DiseaseWithdrawnNCT02667496Phase 2
• Inhaled GM-CSF for Respiratory Virus-Associated Severe PneumoniaWithdrawnNCT02601365Phase 1
• Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous LeukemiaWithdrawnNCT02520102Phase 2
• Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or RecurrentWithdrawnNCT02470559Phase 1
• Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain TumorsCompletedNCT02444546Phase 1
• GM-CSF to Decrease ICU Acquired InfectionsCompletedNCT02361528Phase 3
• A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced MelanomaActive, not recruitingNCT02339571Phase 2/3
• HER2-Peptide Vaccination of Patients With Solid TumorsCompletedNCT02276300Phase 1
• The Immuno-Response to Primary Cryotherapy for the Treatment of Prostate CancerCompletedNCT02250014Phase 1
• Leukine (Sargramostim) for Parkinson's DiseaseCompletedNCT01882010Phase 1
• Sargramostim for Myeloid Dendritic Cell DeficiencyCompletedNCT01871467Phase 1
• Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II MelanomaWithdrawnNCT01826864Phase 3
• A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer.CompletedNCT01789099Phase 1/2
• A Phase I/IIa Study of UV1 Vaccine in Patients With Prostate CancerCompletedNCT01784913Phase 1/2
• Does GM-CSF Restore Neutrophil Phagocytosis in Critical Illness?CompletedNCT01653665Phase 1/2
• Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast CancerCompletedNCT01355393Phase 1/2
• Vaccine Therapy and Sargramostim in Treating Patients With Malignant GliomaCompletedNCT01250470Phase 1
• Reduced Doses of Antimony Plus Ranulocyte Monocyte Colony Stimulating Factor (GM-CSF) for Cutaneous LeishmaniasisCompletedNCT00973128Phase 2
• GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin LymphomaStatus unknownNCT00896519Phase 2
• GM-CSF and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin LymphomaStatus unknownNCT00893477Phase 2
• A Safety/Tolerability and Pharmakokinetic Study of Sargramostim Administrated in the GingivaCompletedNCT00689143Phase 1
• Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By SurgeryActive, not recruitingNCT00669734Phase 1
• Combination Chemotherapy, Radiation Therapy, and Sargramostim Before and After Surgery in Treating Patients With Soft Tissue Sarcoma That Can Be Removed By SurgeryCompletedNCT00652860Phase 2
• Vaccine Therapy and GM-CSF in Treating Patients With CNS LymphomaWithdrawnNCT00621036Phase 2
• Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and GM-CSF in Treating Patients With Recurrent, Refractory, or Metastatic Non-Small Cell Lung CancerTerminatedNCT00569296Phase 1
• Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating Patients With Stage IV MelanomaCompletedNCT00568763Phase 1
• IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable DiseaseCompletedNCT00523159Phase 2
• Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian CancerCompletedNCT00436254Phase 1
• Study of Sargramostim in Moderately to Severely Active Crohn's DiseaseTerminatedNCT00329537Phase 2
• PII Trial of Docetaxel/Prednisone w/Sargramostim for HRPCTerminatedNCT00313482Phase 2
• GM-CSF Before Surgery in Treating Patients With Localized Prostate CancerCompletedNCT00305669Phase 1
• Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic CancerCompletedNCT00304018Phase 1
• Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's DiseaseTerminatedNCT00295165Phase 3
• Rituximab and GM-CSF in Treating Patients With Chronic Lymphocytic LeukemiaTerminatedNCT00265915Phase 2
• Efficacy Study of Sargramostim in the Retreatment of Patients Who Have Crohn's Disease Who Have Previously Responded to Treatment With SargramostimTerminatedNCT00206713Phase 3
• Open-label Trial of Leukine in Active Crohn's DiseaseTerminatedNCT00206700Phase 2
• Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's DiseaseCompletedNCT00206674Phase 3
• Safety and Efficacy Study in the Treatment of Pediatric Crohn's DiseaseTerminatedNCT00206661Phase 1/2
• Study in Patients With Crohn's Disease Who Are Steroid Dependent, Despite Previous Unsuccessful Attempts to Reduce Steroids Due to Worsening of Crohn's DiseaseCompletedNCT00206596Phase 2
• Randomized Phase 2 Trial of Pre-chemotherapy Leukine vs. Leukine-Dexamethasone in Combination With Gemzar & 5-FU in Patients With Metastatic Renal Cell CarcinomaWithdrawnNCT00176280Phase 2

← Sargramostim overview